A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial)

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms CONTINUUM
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 04 Apr 2017 Planned End Date changed from 1 Oct 2020 to 27 Oct 2020.
    • 04 Apr 2017 Planned primary completion date changed from 1 Oct 2020 to 27 Oct 2020.
    • 06 Dec 2016 Results (data cut off ,30 Sep 2015) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top